A Cloud GxP Platform that goes wherever the business needs it

Operational Cost Savings by Qualifying Salesforce for GxP Application Development

Learn how USDM saved a $30B annual revenue, Biopharma company over $500k in license costs by implementing a Salesforce Platform VAP, which created baseline and automated testing as well as risk-based validation.

USDM’s Digital Transformation calls upon long-standing domain expertise to restructure data systems across the enterprise, ensuring continued compliance and reduced risk.

The Situation

  • Leading Biopharma company with over $30B in annual revenue
  • Dozens of platforms used by over 8,000 employees
  • Entrenched belief that Salesforce could not be used in a qualified way
  • Minimal cloud adoption for GxP use cases
  • No compliance framework for assessing, validating and maintaining a validated state for cloud based applications
  • IT viewed as the Wild West, QA viewed as onerous

The Solution

Used Salesforce Platform VAP subscription to create a baseline and automated testing to maintain a compliant state. We then established risk-based validation commensurate with intended use of system, regulatory rigor, technical complexity, business risk, and data integrity risk.
  • Establish robust cloud compliance framework to manage risks
  • VAP provided baseline qualification/validation deliverables
  • Annual Salesforce audit included as part of the subscription
  • Validation augmented by SQA (automated) testing and Functional Risk Assessments Validation vs. Qualification Qualified underlying common capabilities (features and functionality)
  • Established simpler end-use validation based on verifying configurations of common capabilities; user acceptance / PQs; and extensive validation only for unique capabilities

$500k+ SAVED THE FIRST YEAR in license costs via transferring business process automation to Salesforce

We use cookies to understand how you use our site and improve your experience. This includes personalizing content and advertising. Learn more.